Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg Tid in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome.

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg Tid in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2018

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms TARGET-2
  • Sponsors Salix Pharmaceuticals
  • Most Recent Events

    • 06 Dec 2018 According to a Lupin media release, Health Canada has approved ZAXINE 550 mg (rifaximin) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
    • 05 Jun 2018 Results of post hoc pooled analysis from three phase 3 trials examining the efficacy of rifaximin in improving bloating presented at the Digestive Disease Week 2018
    • 03 Jun 2018 According to the Salix Pharmaceuticals media release, pooled analysis results from this and other two trials (TARGET-1 and TARGET-3) will be presented at Digestive Disease Week 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top